Agreements with new and small suppliers aim to increase patient safety, access to drugs on FDA shortage list
CHARLOTTE, N.C. - The Premier healthcare alliance announced new agreements with a broader scope of generic drug manufacturers to provide drugs on the drug shortage list, including bringing new manufacturers into the generic injectable market. This is part of the alliance's ongoing commitment to solve drug shortages for American patients.
The first of these agreements is with Heritage Pharmaceuticals Inc., a subsidiary of Emcure Pharma Ltd., to offer alliance members safer and more reliable access to drugs on the Food and Drug Administration (FDA) shortage list, including:
Ad Statistics
Times Displayed: 114615
Times Visited: 6802 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
* Cidofovir, used to treat viruses in AIDS patients. Heritage received the 2013 Healthcare Distribution Management Association best new generic product introduction of the year award for its launch of Cidofovir.
* Ondansetron, which prevents nausea and vomiting caused by surgery or cancer therapy.
Heritage also has a deep pipeline of products pending at the FDA and is working closely with the FDA to receive expedited review for approval of additional shorted drugs. Under their contracts, Premier will be able to rapidly make the products available to members at specially negotiated pricing and terms.
In addition to Heritage, Premier has signed contracts with a number of emerging suppliers that are investing in the development and production of shorted generic injectables.
"The Premier alliance is determined to lead the effort to solve our nation's drug shortage problem to benefit care providers and the patients they serve," said Michael J. Alkire, Premier's chief operating officer. "We're aggressively exploring all opportunities to bring high-quality suppliers with the capacity to produce shorted drugs to the market. Through our scale, experience and expertise, we're able to assist smaller suppliers and those new to the generic injectable market by adding their products to our contracts and making the FDA aware of these alternate sources."
"Our priority is to provide the best possible care to our patients, and ensuring a reliable supply of essential medication is a critical aspect in that mission," said Don Mabe, R.Ph, MBA, MHA, chair of the National Pharmacy Committee, a panel of pharmacists overseeing the strategic direction of Premier's pharmacy program, and a health system pharmacy executive. "By working to create a healthier marketplace through private sector solutions, we can increase market access and safely enhance stability and supply."
